Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
Transplantation. 2013 Jul 27;96(2):176-81. doi: 10.1097/TP.0b013e318297443b.
The use of kidneys from expanded-criteria donors (ECD) is regarded with caution.
We compared 279 kidney transplant recipients (KTxR) from standard-criteria donors (SCD) and 237 from ECD, transplanted between January 1990 and December 2006. We evaluated the impact of immediate graft function (IGF), slow graft function (SGF), and delayed graft function (DGF) and the drop in estimated glomerular filtration rate (ΔeGFR) ≤ 30% or > 30% during the first year after transplantation on long-term patient and death-censored graft survival (DCGS).
Ten-year patient survival was similar in SCD- or ECD-KTxR (P = 0.38). DCGS was better in SCD-KTxR versus ECD-KTxR (77.3% vs. 67.3%; P = 0.01). DCGS did not differ in either group experiencing IGF (P = 0.17) or DGF (P = 0.12). However, DCGS was worse in ECD-KTxR experiencing SGF (84.9% vs. 73.7%; P = 0.04). Predictors of DCGS were 1-year serum creatinine (hazard ratio, 1.03; P < 0.0001) and ΔeGFR > 30% between 1 and 12 months (Δ1-12eGFR) after transplantation (hazard ratio, 2.2; P = 0.02). In ECD-KTxR with IGF and more than 1-year follow-up, 10-year DCGS was better in those with Δ1-12eGFR ≤ 30% versus those with Δ1-12eGFR > 30% (83.8% vs. 53.6%; P = 0.01).
Recipients of SCD or ECD kidneys with IGF or DGF had similar 10-year patient survival and DCGS. SGF had a worse impact on DCGS in ECD-KTxR. In addition to 1-year serum creatinine, Δ1-12eGFR > 30% is a negative predictor of DCGS. Larger studies should confirm if increasing the use of ECD, avoiding factors that contribute to SGF or DGF, and/or a decline in eGFR during the first year after transplantation may expand the donor pool and result in acceptable long-term outcomes.
使用扩展标准供体(ECD)的肾脏受到谨慎对待。
我们比较了 1990 年 1 月至 2006 年 12 月期间接受标准标准供体(SCD)和 237 例 ECD 肾移植受者(KTxR)的 279 例。我们评估了即刻移植物功能(IGF)、缓慢移植物功能(SGF)和延迟移植物功能(DGF)的影响,以及在移植后 1 年内 eGFR 下降≥30%或>30%对长期患者和死亡风险校正移植物存活率(DCGS)的影响。
SCD-或 ECD-KTxR 的 10 年患者存活率相似(P=0.38)。SCD-KTxR 的 DCGS 优于 ECD-KTxR(77.3% vs. 67.3%;P=0.01)。在任何一组经历 IGF 或 DGF 的患者中,DCGS 均无差异(P=0.17 或 P=0.12)。然而,在经历 SGF 的 ECD-KTxR 中,DCGS 更差(84.9% vs. 73.7%;P=0.04)。DCGS 的预测因素为 1 年血清肌酐(风险比,1.03;P<0.0001)和移植后 1 至 12 个月期间 eGFR 下降>30%(Δ1-12eGFR)(风险比,2.2;P=0.02)。在经历 IGF 和 1 年以上随访的 ECD-KTxR 中,在那些具有 Δ1-12eGFR≤30%的患者中,10 年 DCGS 优于那些具有 Δ1-12eGFR>30%的患者(83.8% vs. 53.6%;P=0.01)。
接受 SCD 或 ECD 肾脏的 IGF 或 DGF 患者的 10 年患者存活率和 DCGS 相似。SGF 对 ECD-KTxR 的 DCGS 有更不利的影响。除了 1 年血清肌酐外,Δ1-12eGFR>30%是 DCGS 的负面预测因子。更大的研究应该证实,是否可以增加 ECD 的使用,避免导致 SGF 或 DGF 的因素,以及/或在移植后 1 年内 eGFR 下降,可能会扩大供体库并带来可接受的长期结果。